Kim Radcliffe
Please note that you can not receive CE credits for watching past webinars.
Discover how the recent U.S. measles outbreak is affecting the workforce and what employers can do to protect their teams. Learn about proactive measures, key industries at risk, and expert insights.
Nikki Wilson examines Journavx, a new FDA-approved nonopioid pain medication, and its potential impact on workers' compensation as a safer alternative to opioids for acute pain management.
Explore the proposed changes to California Workers' Compensation regulations and their potential impacts on workers, employers, and the broader system. Stay informed about how these shifts could reshape the future of compensation policies in the state.
FairPay Flex, Enlyte’s specialty bill review solution, offers significant savings potential for workers' compensation medical bill review. Here are some expert tips and tricks to make the most of this powerful tool.
Buprenorphine, a Schedule III controlled substance approved by the U.S. Food and Drug Administration (FDA), is increasingly being considered for pain management in workers' compensation cases. This partial opioid agonist offers a unique profile that balances effective pain relief with a lower risk of abuse and dependence compared to full opioid agonists.
Enhance your specialty bill review workflow with Enlyte's FairPay Flex. Learn how our dedicated team can resolve disputes and streamline processes.